行情

OCX

OCX

ONCOCYTE
NASDAQ

实时行情|Nasdaq Last Sale

4.430
-0.010
-0.23%
盘后: 4.460 +0.03 +0.68% 19:58 04/22 EDT
开盘
4.450
昨收
4.440
最高
4.680
最低
4.300
成交量
53.07万
成交额
--
52周最高
6.57
52周最低
1.150
市值
3.94亿
市盈率(TTM)
-9.6577
分时
5日
1月
3月
1年
5年
8-K：OncoCyte Corp
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3天前
随着对Chronix Biomedical，Inc.的收购完成，肿瘤细胞进入了快速增长的免疫治疗监测市场。
IRVINE, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing,...
GlobeNewswire · 3天前
新闻稿：肿瘤细胞迅速进入-2-
Dow Jones · 3天前
随着对Chronix Biomedical，Inc.的收购完成，肿瘤细胞进入了快速增长的免疫治疗监测市场> OCX
Oncocyte Enters The Rapidly Growing Immune Therapy Monitoring Market With The Closing Of The Acquisition Of Chronix Biomedical, Inc. >OCX
Dow Jones · 3天前
按业务份额，发展趋势，细分，机会和到2026年的预测进行的乳腺癌预测基因测试市场分析
The Express Wire · 04/16 05:54
Needham对OncoCyte（OCX）给予买入评级
In a report released today, Michael Matson from Needham assigned a Buy rating to OncoCyte (OCX), with a price target of $8.00. The company's shares closed
SmarterAnalyst · 04/14 20:45
全球乳腺癌预测基因测试市场规模，份额，价值和竞争格局2021-2027
Apr 08, 2021 (Heraldkeepers) -- Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive...
Heraldkeepers · 04/08 12:58
每日生物技术脉动：FDA批准默克，帕西拉和西兰，罗氏Regeneron Ace后期COVID-19研究，AlloVir任命Gilead Virology首席执行官为首席执行官
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 22)
Benzinga · 03/23 12:18
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解OCX最新的财务预测，通过OCX每股收益，每股净资产，每股现金流等数据分析ONCOCYTE近期的经营情况，然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测OCX价格均价为7.71，最高价位11.00，最低价为2.000。
EPS
机构持股
总机构数: 82
机构持股: 3,604.95万
持股比例: 40.54%
总股本: 8,891.41万
类型机构数股数
增持
28
230.85万
建仓
14
43.32万
减持
8
13.88万
平仓
12
105.97万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.51%
制药与医学研究
-0.46%
高管信息
Chairman/Independent Director
Cavan Redmond
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Operating Officer
Albert Parker
Senior Vice President/Chief Accounting Officer
Tony Kalajian
Senior Vice President/Director of Marketing
Padma Sundar
Chief Scientific Officer
Lyndal Hesterberg
Other
Douglas Ross
Independent Director
Andrew Arno
Independent Director
Melinda Griffith
Independent Director
Andrew Last
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
OCX 简况
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

微牛提供OncoCyte Corp(NASDAQ-OCX)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的OCX股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易OCX股票基本功能。